- Home
- TXMD vs ESLA Comparison
TXMD vs ESLA Comparison
Compare TXMD & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | ESLA |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 19.1M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TXMD | ESLA |
|---|---|---|
| Price | $1.95 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.7K | ★ 2.7M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | $207.74 | N/A |
| Revenue Next Year | $2.15 | N/A |
| P/E Ratio | $96.50 | ★ N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $1.08 | $0.30 |
| 52 Week High | $2.95 | $3.15 |
Technical Indicators
Market Signals| Indicator | TXMD | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 45.37 |
| Support Level | $1.91 | N/A |
| Resistance Level | $2.15 | $0.51 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 4.98 | 24.31 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.